Standard Biotools Inc (LAB) - Total Assets
Based on the latest financial reports, Standard Biotools Inc (LAB) holds total assets worth $539.64 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See LAB net assets for net asset value and shareholders' equity analysis.
Standard Biotools Inc - Total Assets Trend (2006–2024)
This chart illustrates how Standard Biotools Inc's total assets have evolved over time, based on quarterly financial data.
Standard Biotools Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Standard Biotools Inc's total assets of $539.64 Million consist of 61.4% current assets and 38.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.2% |
| Accounts Receivable | $33.61 Million | 5.5% |
| Inventory | $40.74 Million | 6.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $28.95 Million | 4.7% |
| Goodwill | $111.30 Million | 18.2% |
Asset Composition Trend (2006–2024)
This chart illustrates how Standard Biotools Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Standard Biotools Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Standard Biotools Inc's current assets represent 61.4% of total assets in 2024, a decrease from 85.2% in 2006.
- Cash Position: Cash and equivalents constituted 27.2% of total assets in 2024, down from 68.6% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is goodwill at 18.2% of total assets.
Standard Biotools Inc Competitors by Total Assets
Key competitors of Standard Biotools Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.15 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
|
USA | $139.92 Million |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
India | Rs8.57 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
|
Aligned Genetics Inc
KQ:238120
|
Korea | ₩45.11 Billion |
|
Heramed Ltd
AU:HMD
|
Australia | AU$1.04 Million |
|
Acarix A/S
ST:ACARIX
|
Sweden | Skr48.33 Million |
Standard Biotools Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.38 | 3.76 | 2.17 |
| Quick Ratio | 4.14 | 3.41 | 1.81 |
| Cash Ratio | 1.20 | 1.75 | 0.00 |
| Working Capital | $364.47 Million | $332.99 Million | $63.41 Million |
Standard Biotools Inc - Advanced Valuation Insights
This section examines the relationship between Standard Biotools Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.07 |
| Latest Market Cap to Assets Ratio | 0.59 |
| Asset Growth Rate (YoY) | 89.5% |
| Total Assets | $612.34 Million |
| Market Capitalization | $361.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values Standard Biotools Inc's assets below their book value (0.59x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Standard Biotools Inc's assets grew by 89.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Standard Biotools Inc (2006–2024)
The table below shows the annual total assets of Standard Biotools Inc from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $612.34 Million | +89.54% |
| 2023-12-31 | $323.07 Million | -17.23% |
| 2022-12-31 | $390.31 Million | +41.82% |
| 2021-12-31 | $275.21 Million | -15.26% |
| 2020-12-31 | $324.76 Million | +22.64% |
| 2019-12-31 | $264.81 Million | -12.79% |
| 2018-12-31 | $303.65 Million | +5.67% |
| 2017-12-31 | $287.35 Million | -6.22% |
| 2016-12-31 | $306.39 Million | -17.43% |
| 2015-12-31 | $371.06 Million | -8.96% |
| 2014-12-31 | $407.56 Million | +248.59% |
| 2013-12-31 | $116.92 Million | +2.80% |
| 2012-12-31 | $113.73 Million | +43.37% |
| 2011-12-31 | $79.33 Million | +219.85% |
| 2010-12-31 | $24.80 Million | -22.87% |
| 2009-12-31 | $32.15 Million | -0.62% |
| 2008-12-31 | $32.35 Million | -40.93% |
| 2007-12-31 | $54.78 Million | +50.10% |
| 2006-12-31 | $36.49 Million | -- |
About Standard Biotools Inc
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consum… Read more